Biotec cleared in arbitration matter

(Tromsø, 13. June 2016) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) has today received the decision by the arbitration court related to the Company’s nutrition business brought up by company Sana Pharma AS.

The decision by the arbitration court clears Biotec from all matters sought and the plaintiff will pay the litigation cost for both parties.

-We are very glad for this positive decision by the arbitration court and to put this matter behind us. Despite this ongoing matter we have continued a good working relationship with Sana Pharma and will aim at continue this also going forward, says Svein Lien, CEO in Biotec Pharmacon.

For more information

Svein Lien, CEO
+47 922 89 323

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics